In a regulatory filing, Dyne Therapeutics (DYN) disclosed that its CEO John Cox bought 100K shares of common stock on July 14th in a total transaction size of $911K. Shares are up 9% at $8.99 afterhours.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics price target lowered to $41 from $46 at Evercore ISI
- Dyne Therapeutics’ DYNE-251 Study Update: A Potential Game-Changer for Duchenne Muscular Dystrophy
- Dyne Therapeutics Announces $200M Public Offering
- Morning Movers: Tesla dips as Musk and Trump resume feud
- Dyne Therapeutics 24.2M share Spot Secondary priced at $8.25